CN115651854A - Lactobacillus plantarum YG06 strain and application thereof - Google Patents
Lactobacillus plantarum YG06 strain and application thereof Download PDFInfo
- Publication number
- CN115651854A CN115651854A CN202210511087.3A CN202210511087A CN115651854A CN 115651854 A CN115651854 A CN 115651854A CN 202210511087 A CN202210511087 A CN 202210511087A CN 115651854 A CN115651854 A CN 115651854A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- powder
- strain
- lactobacillus
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 116
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 116
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 116
- 239000003814 drug Substances 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 12
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 8
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 8
- 244000005700 microbiome Species 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 48
- 235000013618 yogurt Nutrition 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 235000013325 dietary fiber Nutrition 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 7
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 7
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 235000010855 food raising agent Nutrition 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical group 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 12
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 238000004321 preservation Methods 0.000 abstract description 4
- 241000218378 Magnolia Species 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 5
- 102100040918 Pro-glucagon Human genes 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 238000013218 HFD mouse model Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- -1 GLP- Chemical compound 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Abstract
The invention discloses a Lactobacillus plantarum YG06 strain, which has been preserved in Guangdong province microorganism strain preservation center at 3/6/2022, wherein the preservation unit is No. 59 building 5 of Michelia Tokyo 100, guangzhou city, and the preservation number is GDMCCNo.62277; the lactobacillus plantarum YG06 disclosed by the invention can be used for preparing foods, health-care products or medicines for reducing weight, improving hyperglycemia and improving cognitive impairment caused by obesity, has better safety, regulates and improves the intestinal microecological balance of a host, exerts beneficial effects and generates exact health efficacy; in vitro and animal experiments show that the Chinese medicinal composition has the functions of strongly reducing weight, improving hyperglycemia and improving cognitive impairment.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a Lactobacillus plantarum YG06 strain and application thereof.
Background
In recent years, the prevalence rate of obesity has rapidly increased, and not only people are widely distributed, but also the health of people is seriously harmed, and medical research has shown that obesity is a well-known main risk factor for many adult-onset chronic diseases such as cardiovascular diseases, type II diabetes, inflammation, fatty liver, hypertension and the like; in addition, obesity may cause psychological and social adaptation problems, such as memory decline, cognitive impairment, social adaptation impairment, and the like, and therefore, prevention of obesity is one of the important measures to reduce the morbidity and mortality of related metabolic diseases.
The intestinal flora refers to microorganisms inhabiting in human intestinal tracts, the intestinal flora is interdependent and restricted to form a dynamic balance system, and interacts with a host to influence the nutrition and health of an organism, and a large number of researches disclose mechanisms of linking several intestinal flora with obesity and metabolic disorder, wherein the mechanisms comprise (1) influence the acquisition of dietary energy of the organism; (2) regulating lipid metabolism of the organism; (3) regulating and controlling the central nervous system of appetite; (4) inducing systemic inflammation.
Probiotics refer to the general term for a class of microorganisms that live, through ingestion in sufficient quantities, to produce one or more specific and demonstrated functional health benefits to a host (WHO, 2011). At present, probiotics are widely applied to the fields of bioengineering, agriculture, food safety and life health, wherein the application of probiotic lactic acid bacteria is the most extensive.
In conclusion, the probiotics capable of reducing weight, improving blood sugar and cognitive impairment are expected to have profound effects on life and health of human beings.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a Lactobacillus plantarum YG06 strain and application thereof, so as to solve the problems in the background art.
(II) technical scheme
In order to achieve the purpose, the invention provides the following technical scheme: the Lactobacillus plantarum YG06 strain and application thereof, the Lactobacillus plantarum YG06 strain has been deposited at the Guangdong province microorganism strain collection center at 3-6.2022, the address of the collection unit is No. 59-5 of the Ministry of Middleu 100, guangzhou city, and the deposition number is GDMCC No.62277.
Preferably, the lactobacillus plantarum YG06 is applied to preparation of medicines, foods, food additives or health products.
Preferably, the medicine, food additive or health product is used for reducing body weight, improving blood sugar and improving cognitive impairment caused by obesity.
Preferably, the food product comprises lactobacillus plantarum YG06 strain, and a dietetically acceptable additive; preferably, the food product is lactobacillus plantarum fermented yoghurt.
Preferably, the lactobacillus plantarum YG06 strain fermented yoghurt is prepared from lactobacillus plantarum powder, milk powder and a leavening agent;
the leavening agent comprises lactobacillus bulgaricus powder and lactobacillus thermophilus powder;
the content of Lactobacillus plantarum YG06 in the Lactobacillus plantarum powder is 1.0 × 10 9 CFU/g；
The total weight of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4% based on the total weight of the lactobacillus plantarum fermented yoghurt;
based on the total weight of the lactobacillus plantarum fermented yogurt, the total weight of the lactobacillus plantarum powder is 1%.
Preferably, the lactobacillus plantarum fermented yoghurt is prepared in the following way:
(1) Carrying out first mixing, homogenizing, sterilizing and first cooling treatment on the milk powder and water, wherein the sterilization is carried out for 300s at 121 ℃, and the temperature after the first cooling treatment is 42 ℃;
(2) Adding the activated leavening agent into the first cooling treatment product to perform fermentation treatment, wherein the fermentation treatment is performed for 10 hours at 42 ℃;
(3) And carrying out second cooling treatment on the fermentation treatment product, and carrying out second mixing treatment on the second cooling treatment product and the lactobacillus plantarum powder so as to obtain the lactobacillus plantarum fermented yoghurt.
Preferably, the medicament comprises lactobacillus plantarum YG06; and a pharmaceutically acceptable non-toxic carrier.
Preferably, the dosage form of the medicament is at least one selected from tablets, granules, powder, capsules, suspending agents, emulsions and freeze-dried preparations; preferably, the medicament is a probiotic tablet.
Preferably, the lactobacillus plantarum tablet comprises: lactobacillus plantarum freeze-dried powder, dietary fiber, sorbitol and magnesium stearate;
the content of lactobacillus plantarum in the lactobacillus plantarum freeze-dried powder is 1.0 multiplied by 10 9 CFU/g；
The dietary fiber in the lactobacillus plantarum freeze-dried powder is galacto-oligosaccharide;
25 parts of lactobacillus plantarum freeze-dried powder and 60 parts of dietary fiber;
the sorbitol is 10 parts by weight, and the magnesium stearate is 5 parts by weight.
(III) advantageous effects
Compared with the prior art, the invention provides the Lactobacillus plantarum YG06 strain and the application thereof, and the strain has the following beneficial effects:
the Lactobacillus plantarum YG06 strain can effectively relieve dyslipidemia caused by diet, improve intestinal flora imbalance induced by high-fat diet, has excellent functions of losing weight, improving blood sugar and improving cognitive impairment, and can be widely applied to preparation of various probiotic foods or health products. Therefore, the strain has great application potential.
Drawings
FIG. 1 shows the body weight change of mice in example 1 of the present invention;
FIG. 2 is the area under the GTT and ITT curves in example 2 of the present invention;
FIG. 3 is a graph showing a blood glucose related index in example 2 of the present invention;
FIG. 4 shows the Y maze experiment result in example 3 of the present invention;
FIG. 5 shows the results of the Barnes maze test in example 3 of the present invention;
FIG. 6 shows the body weight change of mice in example 4 of the present invention;
FIG. 7 is a graph showing the blood glucose related index of mice in example 4 of the present invention;
FIG. 8 shows the Y maze experiment result in example 4 of the present invention;
FIG. 9 shows the results of the Barnes maze test in example 4 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to the attached drawings 1-3, the invention provides a technical scheme, a lactobacillus plantarum YG06 strain and application thereof, wherein the lactobacillus plantarum YG06 strain is preserved in the Guangdong province microorganism strain preservation center at 3-6.2022, the preservation unit is No. 59 building 5 of Michelia furiosa No. 100 Dazhou province in Guangzhou city, the preservation number is GDMCC No.62277, and the name of the biological material is as follows: lactplantibacillus plantarum.
The embodiment of the present invention also provides the use of lactobacillus plantarum YG06 in the preparation of a medicament, a food additive or a health food, where "food" is meant to be understood in a broad sense and can be in any form that can be used, i.e., besides the conventional food form, the food of the present invention can also be a health food, a beverage, a fermented food, etc., such as yogurt, a lactic acid bacteria beverage, a lactic acid bacteria fermented bean product, cheese, a processed food containing fermented yogurt, or a health food, etc.
In this example, the drug, food additive or health product is used for reducing body weight, improving blood glucose and improving cognitive impairment caused by obesity, and is used for non-diagnostic purposes, such as scientific research or health care.
In this example, the food product comprises lactobacillus plantarum YG06 strain, and a dietetically acceptable additive; preferably, the food product is lactobacillus plantarum fermented yogurt.
In this embodiment, the lactobacillus plantarum YG06 strain fermented yoghurt is prepared from lactobacillus plantarum powder, milk powder and a leavening agent;
the leaven comprises lactobacillus bulgaricus powder and lactobacillus thermophilus powder;
the content of Lactobacillus plantarum YG06 in Lactobacillus plantarum powder is 1.0 × 10 9 CFU/g；
Based on the total weight of the lactobacillus plantarum fermented yoghurt, the total weight of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4 percent;
the total weight of the lactobacillus plantarum fermented yoghurt is 1% based on the total weight of the lactobacillus plantarum fermented yoghurt.
In this embodiment, the lactobacillus plantarum fermented yoghurt is prepared in the following manner:
(1) Mixing milk powder with water, homogenizing, sterilizing at 121 deg.C for 300s, and cooling to 42 deg.C;
(2) Adding an activated leaven into the first cooling treatment product for fermentation treatment, wherein the fermentation treatment is carried out for 10 hours at 42 ℃;
(3) And carrying out second cooling treatment on the fermentation treatment product, and carrying out second mixing treatment on the second cooling treatment product and the lactobacillus plantarum powder so as to obtain the lactobacillus plantarum fermented yoghurt.
In this example, the medicament comprises lactobacillus plantarum YG06; and a pharmaceutically acceptable non-toxic carrier.
The dosage form of the medicine is at least one selected from tablets, granules, powder, capsules, suspending agents, emulsions and freeze-drying preparations; preferably, the medicament is a probiotic tablet.
The medicine also comprises pharmaceutically acceptable auxiliary materials. The pharmaceutically acceptable excipients include, but are not limited to: pharmaceutically acceptable carriers, diluents, fillers, binders and other excipients. Such carriers include, but are not limited to, starch or derivatives thereof, lactose, polyethylene glycol; such diluents include, but are not limited to, starch or derivatives thereof, lactose, sucrose, vegetable oils, waxes, fatty acids; fillers include, but are not limited to talc; the adjuvants may also include, for example, preservatives, lubricants, dispersants, flavoring agents, humectants, antioxidants, colorants, stabilizers, buffers, pH adjusters. Such materials may be desirable to aid in the stability of the formulation or to aid in the enhancement of activity or bioavailability or to produce an acceptable mouthfeel or odor upon oral administration.
In this example, the lactobacillus plantarum tablet comprises: lactobacillus plantarum lyophilized powder, dietary fiber, sorbitol, and magnesium stearate;
the content of Lactobacillus plantarum in Lactobacillus plantarum lyophilized powder is 1.0 × 10 9 CFU/g；
Dietary fiber in the lactobacillus plantarum freeze-dried powder is galactooligosaccharide;
25 parts of lactobacillus plantarum freeze-dried powder and 60 parts of dietary fiber;
Example 1 weight loss test
(I) Lactobacillus plantarum YG06 culture and preparation
1. MRS culture medium: the beef cattle feed additive is prepared from casein peptone 10g/L, beef extract 10g/L, yeast extract 5g/L, glucose 20g/L, dipotassium hydrogen phosphate 2g/L, tween 80 g/L, triammonium citrate 2g/L, sodium acetate 5g/L, magnesium sulfate 0.1g/L and manganese sulfate 0.05g/L by adjusting pH to 6.5 and sterilizing at 121 ℃ for 20 min.
2. Inoculating the preserved Lactobacillus plantarum YG06 to MRS liquid culture medium, culturing at 37 deg.C for 24h, centrifuging at 4 deg.C and 12000r/min for 15min, collecting bacterial sludge, adding appropriate amount of lyophilized protectant, and lyophilizing at-80 deg.C for storage.
(II) preparation of gastric lavage reagent
Gavage reagent of drug control group: atorvastatin (blood fat reducing medicine) is prepared into 1mg/mL by using a proper amount of sterile water and is used as it is.
YG06 strain group gavage reagent: re-dissolving Lactobacillus plantarum YG06 strain lyophilized powder with appropriate amount of sterile water until viable count is 10 9 CFU/mL, ready for use.
(III) animal experiment verification
1. Establishing an animal model: after being adaptively fed for one week, 45 7-week-old C57BL/6 male mice were randomly divided into 3 groups of 15 mice each, and the normal group was fed with AIN93M standard diet, and the model group and YG06 group were fed with 60% high fat diet. The body weight level of each mouse was measured after two weeks of induction with high fat diet, and mice whose weight gain did not meet the criteria were removed to ensure successful establishment of the high model, which was recorded as week 0 of administration.
2. Administration treatment: YG06 group was dosed at 0.1mL/10g, and normal and model groups were given an equal volume of sterile water 1 time a day for eight consecutive gavages.
3. Collecting and detecting samples: the body weight of the mice was measured once a week, and the results of the experiment are shown in FIG. 1.
(IV) results of the experiment
From the results in fig. 1, it can be seen that the body weight of the high-fat group was significantly higher than that of the other groups (P < 0.05) within 8 weeks of gavage, and the body weight of the YG06 group was significantly lower than that of the high-fat group (P < 0.05) from the fourth week of gavage, indicating that the lactobacillus plantarum YG06 can reduce the body weight of the high-fat mice.
Example 2 hypoglycemic experiments
The culture and preparation of Lactobacillus plantarum YG06, preparation of gastric lavage reagent, establishment of animal model, and administration treatment were the same as in example 1.
(II) sample collection and detection: after the mice are fed for 8 weeks, the mice are fasted overnight (14 h), blood is taken from the tail of the mice, fasting Blood Glucose (FBG) is measured, then a certain amount of insulin or glucose is injected into the mice, and the blood glucose at 0, 15, 30, 60 and 120min is measured, so that the glucose tolerance (GTT) and the insulin sensitivity (ITT) of the mice are measured. Establishing a standard curve and measuring Fasting Insulin (FINS) and glucagon-like peptide (GLP-1) by adopting an ELISA method according to the kit step operation; calculating Insulin Sensitivity Index (ISI) = I/(FBG × FINS), steady-state pancreatic islet resistance index (HOMA-IR) = FBG × FINS/22.5 (FBG: fasting blood glucose; FINS: fasting insulin)
(III) conclusion of the experiment
The results of glucose tolerance (GTT) and insulin sensitivity (ITT) tests are shown in FIGS. 1a and 1b, and the area under the curved surface is shown in FIG. 2. Therefore, compared with any other group, the glucose tolerance of the high-fat diet group is obviously improved, and the insulin sensitivity is obviously reduced (P < 0.01). And compared with the high-fat group, the YG06 group has obviously reduced glucose tolerance and obviously improved insulin sensitivity (P < 0.01).
The results of fasting plasma glucose, insulin resistance indicators HOMA, GLP-, and Leptin are shown in FIG. 3. The YG06 group had significantly lower fasting plasma glucose and HOMA than the high lipid group (P < 0.05). It was shown that lactobacillus plantarum YG06 can significantly reduce fasting blood glucose and improve insulin resistance.
Glucagon-like peptide-1 (GLP-1) is produced by intestinal tract L cells, has the activity of appetite central nervous system, and can reduce energy intake and relieve obesity by supplementing GLP-1 to the body. The experimental results show that the GLP-1 of the YG06 group is significantly higher than that of the high-fat group (P is less than 0.05), which indicates that the Lactobacillus plantarum YG06 can increase the GLP-1 production, thereby controlling appetite and improving the blood sugar condition.
In conclusion, lactobacillus plantarum YG06 can participate in blood glucose regulation by improving glucose tolerance, increasing insulin sensitivity, and reducing fasting glucose, suppressing appetite.
Example 3 improved cognitive experiments
Lactobacillus plantarum YG06, preparation of gavage agent, establishment of animal model, administration treatment the same as example 1
(II) experimental method:
1.Y maze experiment
In order to detect the autonomous activity ability and the learning and memory functions of the mouse, the tested mouse is placed in a Y-shaped maze device with a three-fork arm channel (20 cm in length, 4cm in width and 40cm in height) and the inner wall of the Y-shaped maze device is dark, the Y-shaped maze device is freely explored under a video monitoring device, and a video device and related software record data such as a walking route, speed, total distance, arm entering times and the like. Each test mouse was placed in the center of the apparatus and started on a 8min timed activity, with 3 repetitions, at intervals greater than 1h.
2. Barnes maze experiment
1) One day prior to the start of the experiment, animals were individually placed in the target chamber from the target hole for acclimation for 4min.
2) The animals were placed in a plastic cylinder (20 cm diameter and 27cm height) in the center of the maze and restrained from movement for 5s.
3) The cylinder was removed and the software started. The four limbs of the animal all entered the target box, and the animal was counted as one escape and allowed to stay in the box for 30s. Each animal was observed once for a maximum of 4min. During this period, if the animal still cannot find the target box, the animal is removed from the maze and placed in the target box for 30s. The labyrinth is cleaned by this gap. Animals were trained 1 time per day for 4 consecutive days.
4) From the second training, the maze was rotated one to several hole positions before each training, but the target box was always fixed in the same direction. The purpose of this is to prevent the animal from relying on the scent and relying on memory to determine the position of the target tank. Latency to reach the target bin and number of errors per animal, etc. were recorded.
5) On the fifth day, the target chamber was removed and the mice were allowed to explore freely for 120s, and the number of times any hole was explored, the dwell time near the target chamber, and the time at which the target chamber was first found were recorded.
(III) test results and analysis
The cognitive function impairment condition of the mice is evaluated by utilizing the Baens maze and the Y maze, and the results are shown in fig. 4 and 5, in the Baens maze, the incubation period of the YG06 group of mice in the second day of training is obviously reduced, in the test day, the exploration times and the staying time of the YG06 group of mice in the target box are obviously improved, and the time for reaching the target box for the first time is reduced; in the Y maze, the percent of alternating success rose. The lactobacillus plantarum YG06 is shown to alleviate cognitive function impairment of HFD mice.
EXAMPLE 4 preparation of food and pharmaceutical products
In this example, lactobacillus plantarum YG06 was prepared into commonly used food and medicine, respectively, as follows:
(1) Lactobacillus plantarum fermented yoghurt
Mixing milk powder and water, homogenizing, sterilizing at 121 deg.C for 300s, cooling to 42 deg.C, inoculating activated starter: the total inoculation amount of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4 percent by weight. Fermenting at 42 deg.C for 10h, cooling, adding 1% by weight of CFU to 10% 9 And (3) stirring and filling the CFU/g of lactobacillus plantarum YG 06.
Wherein the milk powder is milk powder conventionally used in yogurt preparation.
(2) Lactobacillus plantarum tablet
The formula is as follows: 10 9 25% of CFU/g freeze-dried powder of Lactobacillus plantarum YG06, 60% of galactooligosaccharide, 10% of sorbitol and 5% of magnesium stearate; the components are mixed evenly and then tabletted to prepare the tablet. Wherein, the freeze-dried powder of the Lactobacillus plantarum YG06 is prepared by freezing, vacuumizing and drying the bacterial suspension of the Lactobacillus plantarum YG06 in an aseptic environment by a freeze dryer.
(3) Drug effect test of the above foods and drugs
The experimental scheme is as follows: in the same way as in examples 1, 2 and 3, the samples for gastric perfusion were changed into suspension prepared by mashing the above lactobacillus plantarum fermented yoghurt and lactobacillus plantarum tablet and adding sterile water, and the number of bacteria was adjusted to about 2.0 × 10 9 CFU/ml。
As can be seen from FIG. 6, during the gavage period, the weight of the group with high fat was significantly higher than that of any other group (P < 0.05), and the weight of the group with Lactobacillus plantarum fermented cow milk and the group with Lactobacillus plantarum tablet were significantly lower than that of the group with high fat (P < 0.05), so the Lactobacillus plantarum fermented cow milk and the Lactobacillus plantarum tablet according to the present invention had the effect of reducing the weight of the mice with high fat.
As can be seen from FIG. 7, compared with the group with high fat, fasting plasma glucose and HOMA index of the group of the lactobacillus plantarum fermented yogurt and the group of the lactobacillus plantarum tablet were both significantly reduced (P < 0.05), and GLP-1 content was significantly increased. Therefore, the lactobacillus plantarum fermented yoghurt and the lactobacillus plantarum tablet have the effects of reducing fasting blood glucose, improving insulin resistance and inhibiting appetite.
The cognitive function damage condition of the mice is evaluated by utilizing the Baens maze and the Y maze, and the results are shown in figures 8 and 9, in the Baens maze, the latency of the mice with the lactobacillus plantarum fermented yoghurt group and the lactobacillus plantarum tablet group in the second training day is obviously reduced, in the test day, the exploration times of the mice with the lactobacillus plantarum fermented yoghurt group and the lactobacillus plantarum tablet group in the target box and the residence time of the mice in the target box are obviously improved, and the time for the mice to reach the target box for the first time is reduced; in the Y maze, the percent of alternating success rose. The results show that the cognitive function damage of the HFD mice is relieved by the lactobacillus plantarum fermented yoghurt and the lactobacillus plantarum tablet.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Sequence listing
<110> Zhuhai Yiwhat Biotechnology Limited
<120> Lactobacillus plantarum YG06 strain and application thereof
<130> 202104
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1482
<212> DNA
<213> unknown
<400> 1
acaaatctgt cacattaggc ggctggttcg tagaatgagt taccccaccg actttgggtg 60
ttacaaactc tcatggtgtg acgggcggtg tgtacaaggc ccgggaacgt attcaccgcg 120
gcatgctgat ccgcgattac tagcgattcc gacttcatgt aggcgagttg cagcctacaa 180
tccgaactga gaatggcttt aagagattag cttactctcg cgagttcgca actcgttgta 240
ccatccattg tagcacgtgt gtagcccagg tcataagggg catgatgatt tgacgtcatc 300
cccaccttcc tccggtttgt caccggcagt ctcaccagag tgcccaactt aatgctggca 360
actgataata agggttgcgc tcgttgcggg acttaaccca acatctcacg acacgagctg 420
acgacaacca tgcaccacct gtatccatgt ccccgaaggg aacgtctaat ctcttagatt 480
tgcatagtat gtcaagacct ggtaaggttc ttcgcgtagc ttcgaattaa accacatgct 540
ccaccgcttg tgcgggcccc cgtcaattcc tttgagtttc agccttgcgg ccgtactccc 600
caggcggaat gcttaatgcg ttagctgcag cactgaaggg cggaaaccct ccaacactta 660
gcattcatcg tttacggtat ggactaccag ggtatctaat cctgtttgct acccatactt 720
tcgagcctca gcgtcagtta cagaccagac agccgccttc gccactggtg ttcttccata 780
tatctacgca tttcaccgct acacatggag ttccactgtc ctcttctgca ctcaagtttc 840
ccagtttccg atgcacttct tcggttgagc cgaaggcttt cacatcagac ttaaaaaacc 900
gcctgcgctc gctttacgcc caataaatcc ggacaacgct tgccacctac gtattaccgc 960
ggctgctggc acgtagttag ccgtggcttt ctggttaaat accgtcaata cctgaacagt 1020
tactctcaga tatgttcttc tttaacaaca gagttttacg agccgaaacc cttcttcact 1080
cacgcggcgt tgctccatca gactttcgtc cattgtggaa gattccctac tgctgcctcc 1140
cgtaggagtt tgggccgtgt ctcagtccca atgtggccga ttaccctctc aggtcggcta 1200
cgtatcattg ccatggtgag ccgttacccc accatctagc taatacgccg cgggaccatc 1260
caaaagtgat agccgaagcc atctttcaag ctcggaccat gcggtccaag ttgttatgcg 1320
gtattagcat ctgtttccag gtgttatccc ccgcttctgg gcaggtttcc cacgtgttat 1380
atcaccagtt cgccactcac tcaaatgtaa atcatgatgc aatagcctaa tctaatactc 1440
agagttcgtt cgactatcac gtatctagct agctcgcaca at 1482
Claims (9)
1. A lactobacillus plantarum YG06 strain, characterized in that: the lactobacillus plantarum YG06 has been deposited at the Guangdong province microorganism culture collection center at 3/6.2022, the address of the collection unit is No. 59 building 5 of Mirabilitum 100, guangzhou city, and the number is GDMCC No.62277.
2. The Lactobacillus plantarum YG06 strain of claim 1, and its use, wherein: the Lactobacillus plantarum YG06 is applied to preparation of medicines, foods, food additives or health products.
3. The YG06 strain of Lactobacillus plantarum according to claim 2, wherein: the medicine, food additive or health product is used for reducing body weight, improving blood sugar and improving cognitive impairment caused by obesity.
4. The YG06 strain of Lactobacillus plantarum according to claim 3, wherein: the food product comprises a Lactobacillus plantarum YG06 strain, and a bromatologically acceptable additive; preferably, the food product is lactobacillus plantarum fermented yoghurt.
5. The YG06 strain of Lactobacillus plantarum according to claim 4, wherein: the lactobacillus plantarum YG06 strain fermented yoghurt is prepared from lactobacillus plantarum powder, milk powder and a leavening agent;
the leaven comprises lactobacillus bulgaricus powder and lactobacillus thermophilus powder;
the content of Lactobacillus plantarum YG06 in the Lactobacillus plantarum powder is 1.0 × 10 9 CFU/g；
The total weight of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4% based on the total weight of the lactobacillus plantarum fermented yoghurt;
based on the total weight of the lactobacillus plantarum fermented yogurt, the total weight of the lactobacillus plantarum powder is 1%.
6. The YG06 strain of Lactobacillus plantarum according to claim 5, wherein: the lactobacillus plantarum fermented yoghurt is prepared by the following preparation method:
(1) Carrying out first mixing, homogenizing, sterilizing and first cooling treatment on the milk powder and water, wherein the sterilization is carried out for 300s at 121 ℃, and the temperature after the first cooling treatment is 42 ℃;
(2) Adding the activated leavening agent into the first cooling treatment product to perform fermentation treatment, wherein the fermentation treatment is performed for 10 hours at 42 ℃;
(3) And carrying out second cooling treatment on the fermentation treatment product, and carrying out second mixing treatment on the second cooling treatment product and the lactobacillus plantarum powder so as to obtain the lactobacillus plantarum fermented yoghurt.
7. The YG06 strain of Lactobacillus plantarum according to claim 3, wherein: the medicament comprises lactobacillus plantarum YG06; and a pharmaceutically acceptable non-toxic carrier.
8. The YG06 strain of Lactobacillus plantarum according to claim 7, wherein: the dosage form of the medicine is at least one selected from tablets, granules, powder, capsules, suspending agents, emulsions and freeze-dried preparations; preferably, the medicament is a probiotic tablet.
9. The YG06 strain of Lactobacillus plantarum according to claim 8, wherein: the lactobacillus plantarum tablet comprises: lactobacillus plantarum lyophilized powder, dietary fiber, sorbitol, and magnesium stearate;
the content of Lactobacillus plantarum in the Lactobacillus plantarum freeze-dried powder is 1.0 multiplied by 10 9 CFU/g；
The dietary fiber in the lactobacillus plantarum freeze-dried powder is galactooligosaccharide;
25 parts of lactobacillus plantarum freeze-dried powder and 60 parts of dietary fiber;
the sorbitol is 10 parts by weight, and the magnesium stearate is 5 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511087.3A CN115651854A (en) | 2022-05-11 | 2022-05-11 | Lactobacillus plantarum YG06 strain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511087.3A CN115651854A (en) | 2022-05-11 | 2022-05-11 | Lactobacillus plantarum YG06 strain and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115651854A true CN115651854A (en) | 2023-01-31 |
Family
ID=85024206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210511087.3A Pending CN115651854A (en) | 2022-05-11 | 2022-05-11 | Lactobacillus plantarum YG06 strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115651854A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116814505A (en) * | 2023-08-11 | 2023-09-29 | 顾建文 | Lactobacillus rhamnosus and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090113478A (en) * | 2008-04-28 | 2009-11-02 | 주식회사 엔유씨전자 | Probiotic Lactobacillus plantarum having anti-obesity and brain function improvement activity |
| CN113812634A (en) * | 2021-09-22 | 2021-12-21 | 深圳市华大农业应用研究院 | Synbiotic composition and preparation method and application thereof |
-
2022
- 2022-05-11 CN CN202210511087.3A patent/CN115651854A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090113478A (en) * | 2008-04-28 | 2009-11-02 | 주식회사 엔유씨전자 | Probiotic Lactobacillus plantarum having anti-obesity and brain function improvement activity |
| CN113812634A (en) * | 2021-09-22 | 2021-12-21 | 深圳市华大农业应用研究院 | Synbiotic composition and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 何俊成: "益生元组合对高脂饮食诱导小鼠肥胖的调控机制", 《中国优秀硕士学位论文全文数据库》, pages 057 - 372 * |
| 孟晓等: "植物乳杆菌SCS1对高血糖模型小鼠的降血糖作用", 《食品工业科技》, vol. 37, no. 2, pages 352 - 357 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116814505A (en) * | 2023-08-11 | 2023-09-29 | 顾建文 | Lactobacillus rhamnosus and application thereof |
| CN116814505B (en) * | 2023-08-11 | 2024-04-19 | 顾建文 | Lactobacillus rhamnosus and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107502575B (en) | Lactobacillus plantarum with high alpha-glucosidase inhibition activity | |
| US10226490B2 (en) | Probiotic compositions and methods for inducing and supporting weight loss | |
| US20150037286A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
| CN111346114A (en) | Application of lactobacillus reuteri | |
| CN110218681B (en) | Lactobacillus fermentum KP101 and application thereof | |
| CN103275905A (en) | Lactobacillus rhamnosus CCFM0528 having diabetes preventing effect | |
| US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| US20220151253A1 (en) | Kimchi lactic acid bacteria lactobacillus sakei wikim0109 having efficacy for relief of arthritis | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| TW201043151A (en) | Agent for preventing or improving obesity | |
| CN115089619A (en) | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease | |
| CN113881597B (en) | Lactobacillus reuteri capable of improving indole acrylic acid to regulate specific IgE | |
| CN115651854A (en) | Lactobacillus plantarum YG06 strain and application thereof | |
| CN107412272A (en) | Application of the Lactobacillus plantarum in gut barrier injury is prevented | |
| US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| CN111035658A (en) | Use of pediococcus pentosaceus | |
| CN113812634A (en) | Synbiotic composition and preparation method and application thereof | |
| CN113164530A (en) | Application of enterococcus faecalis | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN114686405A (en) | Bifidobacterium bifidum capable of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN111714522B (en) | Bacteroides and application thereof | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN113913330B (en) | Lactobacillus plantarum for regulating OVA-specific IgE and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |